|
SKIN AND SKIN STRUCTURE Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes. Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CEFZIL and other antibacterial drugs, CEFZIL should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemi-ology and susceptibility patterns may contribute to the empiric selection of therapy. Text Continues Below

DOSAGE AND ADMINISTRATION CEFZIL (cefprozil) is administered orally. Dosage Duration Population/ Infection (mg) (days) ADULTS (13 years and older) UPPER RESPIRATORY TRACT Pharyngitis / Tonsillitis 500 q24h 10 a Acute Sinusitis 250 q12h or 10 (For moderate to severe infections, 500 q12h the higher dose should be used) LOWER RESPIRATORY TRACT Secondary Bacterial Infection 500 q12h 10 of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis SKIN AND SKIN STRUCTURE Uncomplicated Skin and 250 q12h or 10 Skin Structure Infections 500 q24h or 500 q12h CHILDREN (2 years -12 years) UPPER RESPIRATORY TRACT b Pharyngitis / Tonsillitis 7.5 mg/ kg 10 a q12h SKIN AND SKIN STRUCTURE b Uncomplicated Skin and 20 mg/ kg 10 Skin Structure Infections q24h INFANTS & CHILDREN (6 months -12 years) UPPER RESPIRATORY TRACT b Otitis Media 15 mg/ kg 10 (See INDICATIONS AND USAGE q12h and CLINICAL STUDIES) Acute Sinusitis 7.5 mg/ kg 10 (For moderate to severe infections, q12h or the higher dose should be used) 15 mg/ kg a In the treatment of infections due to Streptococcus pyogenes, CEFZIL should be administered for at least 10 days. b Not to exceed recommended adult doses. Clinitest ® and Clinistix ® are registered trademarks of Bayer HealthCare LLC. Page: << Prev | 1 | 2 | 3 | 4 | 5 | Next >>
|